Walleye Capital’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
Walleye Capital's RNA Position: Q3 2026 in Review
Walleye Capital opened a new position in Atrium Therapeutics (RNA) in Q3 2026: 4,618 shares worth $38.2K. The stake represents ﹤0.01% of the portfolio and ranks #5515 among its holdings.
148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- Walleye Capital held 4,618 shares of Atrium Therapeutics worth $38.2K as of Q3 2026.
- Atrium Therapeutics was a new Walleye Capital position in Q3 2026.
- Atrium Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #5515 holding.
- 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.